FDA Approved: NEULASTA — Supplemental Application (Amgen, Inc)

View source ↗

Summary

FDA approves a supplemental application for NEULASTA (pegfilgrastim) filed by Amgen, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Chemotherapy-induced Neutropenia
• Febrile Neutropenia
• Neutropenia

Drugs mentioned

• NEULASTA (pegfilgrastim)

Snippet

SUPPL AP for NEULASTA (PEGFILGRASTIM)